

遠隔ICD監視を用いることに関して安全性への疑念はない

EVATEL：植込み型除細動器装着患者の遠隔フォローアップに関する安全性および有効性に疑念はない

EVATEL: Safety and efficacy not compromised with remote follow-up of patients with implantable cardioverter defibrillators

EVATEL（電話によるフォローアップの評価：EVALuation of TELe follow-up）の結果が2011年European Society of Cardiology学会で発表され、植込み型除細動器（ICDs）装着患者の遠隔フォローアップによる安全性および有効性に疑念がないことが示された。このスタディには、フランスの30施設のICD患者1,501人（平均年齢50歳、男性85%）が組み入れられ3か月ごとに1年間追跡された。半分の患者には植え込まれた施設で従来通りのフォローアップが行われ、残りの半分は遠隔的にフォローされた（デバイスに蓄積されたデータは患者の家から施設まで電話で転送され、データはウェブサイトでアクセスできた）。一次エンドポイント（死亡の合計[総死亡]、心血管疾患による入院、デバイスによる無効または不適切な治療の伝達）はコントロール群の28.5%および遠隔群の30.2%において確認され、有意差はなかった。初回の一次エンドポイント発現までの時間（ $p=0.71$ ）および1年後の生存率（ $p=0.31$ ）にも2群間で有意差はなかった。不適切な治療の数は遠隔群においてコントロール群よりも少なかった（それぞれ4.7%と7.5%、 $p=0.03$ ）。しかしながら、このトライアルの厳格な非劣性マージンの5%による非劣性は証明できなかった。

Full Text

Results from the EVATEL (EVALuation of TELe follow-up) trial, reported at the 2011 ESC Congress, are the first in Europe to demonstrate potential safety and efficacy benefits from the remote follow-up of ICD patients. The trial was conducted in France, with the financial support of the French Ministry for Health and independent of any manufacturer grants.

ICDs (implantable cardioverter defibrillators) are devices routinely implanted in patients at risk of sudden cardiac death as a result of rhythm disturbances. The expanding indications for ICDs are expected to have an impact on follow-up strategy, as the number of patients with ICDs is increasing rapidly.

"Currently," explains investigator Dr. Philippe Mabo from the University Hospital of Rennes, France, "regular in-clinic follow-up must be performed every three months, according to manufacturer guidelines. But there are two drawbacks to the in-clinic follow-up - they're time-constrained for both the patient and the clinic, and there's no link between the time of the appointment and the clinical event or device malfunction. So there's a clinical need to consider new follow-up strategy."

In response, several manufacturers have developed new technologies that allow the remote transmission of information from the device and on its therapeutic effect. Critical data can be transmitted at any time on system integrity or unexpected events - for example, lead integrity, battery status or ineffectively delivered therapy. Data stored in the device are transmitted by phone from the patient's home to the implant center, with website access to the data.

"In this context," said Dr. Mabo, "remote device follow-up seems to be a promising technique for device follow-up. But the technology needed clinical validation in terms of safety, efficacy and cost-efficiency, which were the objectives of the EVATEL trial."

The study included 1501 patients from 30 French centers enrolled between January 2008 and January 2010. They were each followed-up every three months for an overall period of one year. The last follow-up was performed in January 2011. The characteristics of the subjects were comparable to those of an ICD trial or registry, with a mean age of 59 years and the majority male (85%). Half the patient received conventional follow-up at the implant center, the other half were followed remotely. The primary end-point of the trial was a clinical composite of death (all causes), cardiovascular hospitalization, and ineffective or inappropriate therapy delivered by the device.

The primary endpoint was validated in 28.5% of the control group and 30.2% of the remote group, thus indicating no difference in outcome between the groups. In addition, there were no statistically significant differences between the two groups in time to occurrence of the first primary endpoint ($p=0.71$) and the one-year survival rate ($p=0.31$). The number of inappropriate therapies was lower in the remote group (4.7%) as compared to the control group (7.5%) ($p=0.03$).

Nevertheless, the non-inferiority hypothesis of the trial with a strict non-inferiority margin of 5% was not confirmed, as the event rate difference between the two groups was 1.7%, with a 95% confidence interval of -0.3 to 6.4.

Commenting on the results, Dr. Mabo said: "The remote follow-up of patients implanted with an ICD seems to be a safe alternative to conventional in-office follow-up. However, for the widespread uptake of this new strategy - at least in France - reimbursement from the healthcare system will be needed. We hope that it will be available soon in France."

Conference News

[News 01]

心房細動においてapixabanはワルファリンよりも優れている

[News 02]

3枝病変に対しCABGは依然としてPCIよりも望ましい

[News 03]

子供に対する予防教育により親のリスクが改善する

[News 04]

VADを用いた心移植のブリッジは問題がある

[News 05]

第二世代の薬剤溶出ステントの方が安全性プロファイルが良好であることが示された

[News 06]

二次予防ストラテジーが過少使用されている

[News 07]

トライアルの結果、長期抗血小板療法の有効性に異議が唱えられた

[News 08]

用量設定試験においてdarexabanは出血を増加させることが示された

[News 09]

MitraClip治療はCRT不成功の場合の選択肢である

[News 10]

遠隔ICD監視を用いることに関して安全性への疑念はない

[News 11]

急性STEMI後のIABCによる有益性は認められない

[News 12]

スタディの結果、薬剤溶出ステントの非劣性が確認された

[News 13]

バイオマーカーカテプシン Sにより死亡リスクが上昇する

[News 14]

再発性心膜炎の予防薬としてのコルヒチン

[News 15]

Dalcetapibの血管機能に対する効果

[News 16]

グループ療法はうつ病を有する心疾患患者に役立つ

[News 17]

精神的ストレスは血管機能に悪影響を及ぼす